Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Ранг среди акций #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Цена акции
$0.5225
Последняя синхронизация: 2026-08-14
Рыночная капитализация
$4.32M
Изменение (1 день)
-1.60%
Изменение (1 год)
-63.72%
Страна
IL
Торговля Galmed Pharmaceuticals Ltd. (GLMD)

Категория

Коэффициент P/S для Galmed Pharmaceuticals Ltd. (GLMD)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Galmed Pharmaceuticals Ltd., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Galmed Pharmaceuticals Ltd. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE